Invitae IPO
Invitae is a medical genetics company that provides genetic testing services for hereditary disorders, cancer predisposition, and other genetic conditions. The company aims to make genetic testing more accessible and affordable for patients and healthcare providers. Invitae offers comprehensive genetic testing panels and genetic counseling services to support clinical decision-making.
Key Facts
| Industry | Biotechnology |
| Founded | 2010 |
| Headquarters | San Francisco, CA |
| Employees | ~1,500 |
| Website | invitae.com |
| Funding | Public company (NYSE: NVTA). Filed for bankruptcy in 2024 |
About Invitae
Invitae is a medical genetics company that provides comprehensive genetic testing services to patients, healthcare providers, and biopharmaceutical companies. The company offers one of the largest panels of genetic tests available, covering areas including hereditary cancer, cardiology, neurology, and rare diseases. Their platform combines advanced sequencing technology with clinical interpretation to help healthcare providers make informed treatment decisions and enable patients to understand their genetic health risks.
The company has pursued an aggressive growth strategy through acquisitions, integrating companies like ArcherDX and Ciitizen to expand their capabilities in oncology testing and health data management. Invitae's vision is to make genetic testing routine in healthcare by reducing costs and improving accessibility. Despite facing financial challenges and undergoing restructuring in recent years, the company continues to process hundreds of thousands of genetic tests annually and maintains partnerships with major healthcare systems and pharmaceutical companies for drug development and clinical trials.
IPO Status
Invitae went public in February 2015, trading on NYSE under the ticker symbol NVTA. The company's IPO raised approximately $45 million at $7 per share. Since going public, Invitae has grown significantly through acquisitions and expansion of its testing menu, becoming one of the larger players in the genetic testing market. As a public company, Invitae has focused on scaling its operations and reducing the cost of genetic testing while expanding its reach to more patients and healthcare providers. The company has made numerous acquisitions to expand its capabilities and has worked to build a comprehensive platform for genetic testing and data analysis.
Competitors
Frequently Asked Questions
Does Invitae have a stock?
Yes, Invitae has been a public company since February 2015. The company went public on NYSE under the ticker symbol NVTA.
When is the Invitae IPO date?
Invitae completed its IPO in February 2015, raising approximately $45 million at $7 per share. The company has been publicly traded for nearly a decade.
How can I buy Invitae stock?
You can buy Invitae stock through any brokerage account as it trades publicly on NYSE under the ticker symbol NVTA. The stock is available through standard online and traditional brokerage services.
Don't Miss the Next Big IPO
Get notified when the next major company files for an IPO. Daily alerts delivered to your inbox.
Get IPO Alerts